The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer.
The feasibility of adjuvant carboplatin and docetaxel in patients with curatively resected non-small cell lung cancer. J Thorac Oncol. 2008 Feb; 3(2):145-51.